Full-Time

Senior Director

Corporate Law & Transactions

Updated on 9/4/2026

Kardigan

Kardigan

201-500 employees

Biotech firm developing cardiovascular medicines

Compensation Overview

$263k - $357k/yr

South San Francisco, CA, USA + 1 more

More locations: Princeton, NJ, USA

Hybrid

Four days on-site per week, Monday through Thursday, are required.

JD

Category
Legal (1)
Required Skills
FDA Regulations
Risk Management

Get referred to Kardigan

See people who can refer or advise you

Requirements
  • A Juris Doctor degree from an accredited law school with admission to practice law.
  • A minimum of 12 years of legal experience with a mix of law firm and in-house experience at pharmaceutical, biotechnology, or medical device companies, focused on contracts and commercial transactions and including substantial hands-on experience with clinical-development-related agreements.
  • The ability to influence business decisions and serve as a trusted advisor to senior leaders by balancing legal, operational, and commercial considerations in a growth-stage environment.
  • Expertise in drafting and negotiating complex agreements.
  • Experience providing legal counsel for managing external business relationships and collaborations.
  • A solid understanding of intellectual property, licensing, privacy, and data protection laws as they relate to strategic agreements and life science transactions.
  • Knowledge of healthcare, FDA regulations, and other relevant laws applicable to life science business transactions, including laws and regulations impacting clinical research.
  • The ability to connect issues across functional areas and identify how legal issues in one domain may impact other business operations.
  • A strong systems-thinking approach to understanding complex interdependencies and anticipating downstream effects of legal or business decisions.
  • A proven track record of translating complex legal concepts into practical business implications.
  • Skill in facilitating cross-functional dialogue to ensure alignment between legal strategies and business objectives.
  • Experience serving as a bridge between technical, business, and legal stakeholders to drive solutions.
  • Strong organizational and planning skills, with the ability to manage changing priorities and workflow and effectively advance multiple simultaneous projects.
  • Strong interpersonal, written, and verbal communication skills, with the ability to communicate and collaborate with individuals at all levels inside and outside the organization.
  • The ability to operate in a fast-paced, rapidly growing workplace while providing a consistently high level of service.
  • The ability to work independently while exercising initiative and good judgment.
Responsibilities
  • Partner closely with Business Development, Technical Operations, Supply, R&D, and other key functions to provide proactive legal support on strategic initiatives, new business opportunities, and alliance management.
  • Partner with Business Development and functional leaders to establish and evolve the alliance management framework, including governance structures, decision-making processes, escalation pathways, and management of strategic collaborations.
  • Serve as a trusted advisor to senior leadership and a cross-functional business partner, helping shape commercial, operational, and strategic decisions while positioning Legal as an enabler of growth.
  • Partner with HR on strategic legal initiatives, including developing and implementing a framework for contractor and contingent workforce management.
  • Partner with business leaders to identify and solve operational, compliance, governance, and commercial challenges as the company scales.
  • Partner directly with senior leadership to evaluate and execute strategic business initiatives related to external partnerships, operational priorities, risk management, and organizational growth.
  • Build scalable policies, frameworks, and processes across the organization.
  • Lead or support cross-functional special projects involving Legal, HR, Finance, Compliance, Clinical Operations, Technical Operations, and Business Development.
  • Provide legal and strategic guidance on workforce models, consultant and contingent worker engagement, and other operational matters.
  • Evaluate and implement systems, technology, and process improvements that enhance business efficiency and reduce legal risk.
  • Serve as a trusted advisor and thought partner to senior leadership on emerging business needs and organizational priorities.
  • Lead the negotiation and drafting of high-value, complex strategic agreements, including collaboration agreements, alliance agreements, licensing and co-development transactions, technical agreements, supply and manufacturing agreements, service agreements, sponsored research agreements, material transfer agreements, and other commercial and strategic transactions.
  • Provide strategic counsel on structure, risk allocation, and terms to optimize business outcomes and protect company interests across commercial and strategic relationships.
  • Provide strategic guidance on transaction structure and contract terms while managing legal risk.
  • Develop and maintain contract templates, playbooks, and standardized contract terms.
  • Identify and mitigate legal risks in business operations and commercial relationships, with emphasis on strategic and general transactions, intellectual property, data protection, and regulatory considerations.
  • Update and improve contract policies and procedures.
  • Train business teams on contract policies, procedures, risk management, and other legal practices.
  • Help shape the structure, processes, and operating model of the Legal transactions function, including playbooks, contracting frameworks, AI-enabled workflows, and legal technology solutions.
  • Establish metrics and reporting systems to track the efficiency and effectiveness of contracting procedures and other legal practices.
  • Manage outside legal consultants and counsel for specialized matters and overflow work as needed.
  • Assist and support with special projects and initiatives.
  • Perform other duties as directed by the manager.
Desired Qualifications
  • Motivation and enthusiasm, with a proactive approach to solving legal and business challenges.

Kardigan develops medicines to prevent and treat cardiovascular disease. It focuses on discovering and developing multiple cardiovascular therapies at a rapid pace, using deep expertise in heart-health drug development to move candidates from research toward commercialization. Their product approach centers on creating medicines that address heart disease more effectively and earlier in the disease process. Kardigan differentiates itself through a leadership team of seasoned biopharma veterans and a commitment to modernizing how cardiovascular drugs are discovered and developed, aiming to bring therapies to patients faster and more efficiently. The company’s goal is to reduce the global burden of cardiovascular disease by providing safe, effective medicines that prevent progression or cure conditions related to heart health.

Company Size

201-500

Company Stage

IPO

Headquarters

South San Francisco, California

Founded

2023

Get referred to Kardigan

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • June 2026 IPO raised $460 million gross, lifting cash to $660.7 million.
  • August 2026: KINSHIP-DCM Phase 3 started, while KARDINAL-ASH enrolled its first patient.
  • ESC 2026 presentations and 1H 2027 topline data keep multiple catalysts ahead.

What critics are saying

  • Kardigan reported $116.2 million Q2 2026 losses, burning IPO cash quickly.
  • All three programs need successful 1H 2027 readouts; one failure could erase valuation.
  • No product revenue exists; another financing round before 2028 would dilute shareholders.

What makes Kardigan unique

  • Tassos Gianakakos and Jay Edelberg built MyoKardia’s mavacamten playbook, then Kardigan.
  • Kardigan pairs Prolaio AI with late-stage cardio trials for narrower, faster registrational studies.
  • Danicamtiv, ataciguat, and tonlamarsen target separate unmet cardiovascular niches without approved therapies.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Hybrid Work Options

Growth & Insights and Company News

Headcount

6 month growth

15%

1 year growth

15%

2 year growth

30%
MarketScreener
Jun 18th, 2026
Kardigan makes strong Nasdaq debut following upsized IPO.

Kardigan makes strong Nasdaq debut following upsized IPO. Kardigan delivered a notable market debut on the Nasdaq, raising $400m in an upsized initial public offering. Shares of the cardiovascular treatment specialist opened at $16.25, above the $16 IPO price, before climbing more than 22% during the session. This performance underscores a resurgence in investor appetite for biotechnology firms boasting advanced clinical programs and robust growth prospects. Published on 06/18/2026 at 03:52 pm EDT Based in Princeton, New Jersey, Kardigan is developing several precision therapies for cardiovascular diseases. Its pipeline notably includes drug candidates danicamtiv, ataciguat, and tonlamarsen. Management has indicated that pivotal data regarding these three programs are expected during the first half of next year. The company was founded by Tassos Gianakakos and Jay Edelberg, two former executives who played key roles in the development of the heart medication mavacamten at MyoKardia, which was acquired by Bristol Myers Squibb for $13bn in 2020. This transaction takes place within a more favorable environment for biotech IPOs following several years defined by tighter access to capital. However, analysts point out that Kardigan may require additional financing in the medium term. The company stated in its regulatory filings that its current resources would not be sufficient to fund operations for at least twelve months without further capital injections, even though the funds raised are intended to accelerate the development of its clinical programs. (C) MarketScreener.com - 2026

IPO Scoop
Jun 18th, 2026
Kardigan

Disclaimer: A SCOOP Rating (Wall Street Consensus of Opening-day Premiums), is a general consensus taken, at press time, from Wall Street and investment professionals concerning how well an IPO might perform when it starts trading. The SCOOP Rating does not reflect the opinions of anyone associated with IPOScoop.com. The SCOOP ratings should not be taken as investment advice. The rating merely reflects the opinion of the professionals at the time of publication and is subject to last-minute changes due to market conditions, changes in a specific offering and other factors, such as changes in the proposed offering terms and the shifting of investor interest in the IPO. The information offered is taken from sources we believe to be reliable, but we cannot guarantee the accuracy.

StockTitan
Jun 18th, 2026
Kardigan prices upsized $400M IPO at $16 per share on Nasdaq

Kardigan, a clinical-stage precision therapeutics company developing treatments for cardiovascular diseases, has priced its initial public offering of 25 million shares at $16 per share. The offering is expected to generate gross proceeds of $400 million before underwriting discounts and expenses. The company has granted underwriters a 30-day option to purchase an additional 3.75 million shares. Kardigan's shares are expected to begin trading on the Nasdaq Global Market on 18 June 2026 under the ticker symbol "KARD", with the offering closing on 22 June 2026. J.P. Morgan Securities, Jefferies, Leerink Partners and TD Securities are serving as underwriters. Based in South San Francisco and Princeton, Kardigan focuses on developing medicines targeting cardiovascular diseases without approved treatments.

pharmaphorum
Jun 18th, 2026
Heart drug biotech Kardigan raises $400m in upscaled IPO.

Heart drug biotech Kardigan raises $400m in upscaled IPO. Cardiovascular drug developer Kardigan has completed its IPO, and in common with the prevailing trend in Nasdaq listings this year, has raised substantially more than it originally anticipated. The gross proceeds have come in at around $400 million, with 25 million shares sold for $16 apiece, which compares to Kardigan's earlier objective of selling 23.3 million at a range of $14 to $16. The final tally could be increased by another $60 million or so if underwriters take up an option to buy another 3.75 million shares at the final price. The proceeds - which top up cash reserves of around $287 million held by Kardigan at the end of March - will go towards the company's three clinical-stage drug candidates, which are all in late-stage development, along with R&D and general corporate purposes. Between $80 million and $90 million is earmarked for danicamtiv, an oral cardiac myosin activator for dilated cardiomyopathy (DCM) driven by MYH7 and TTN gene variants in genes coding for the sarcomere, the functional unit of muscle tissue. That should allow Kardigan to complete an ongoing phase 2b trial and the start of phase 3 development, according to its IPO prospectus. The company has allocated the same amount to ataciguat, a once-daily, oral soluble guanylate cyclase (sGC) activator for calcific aortic valve stenosis (CAVS), and $40 million to $50 million for tonlamarsen, an angiotensinogen-targeted subcutaneous antisense oligonucleotide for blood pressure management in acute severe hypertension (ASH). Once again, that should fund the completion of ongoing phase 2b studies of the two drugs and the start of phase 3, with another $50 million to $60 million pledged to other R&D activities. That includes the further development of its Prolaio platform for applying AI to cardiovascular drug development, which it acquired for up to $200 million. Phase 2b data from the KINSHIP-DCM trial of danicamtiv is due in the first half of 2027, with a series of readouts from the KATALYST-AV study of ataciguat and the KARDINAL study of tonlamarsen also expected next year. Founded by former executives from MyoKardia - which was bought by Bristol Myers Squibb for $13.1 billion in 2020 - Kardigan is based in Princeton, New Jersey, with a second site in South San Francisco. Kardigan's stock is due to start trading on the Nasdaq tomorrow under the KARD ticker symbol. 18 June, 2026

Caproasia
Jun 14th, 2026
United States heart drug biotech company Kardigan Nasdaq IPO to raise $373 million at $1.4 billion valuation with expected IPO listing on 18th June 2026, co-founded in 2023 by Tassos Gianakakos.

United States heart drug biotech company Kardigan Nasdaq IPO to raise $373 million at $1.4 billion valuation with expected IPO listing on 18th June 2026, co-founded in 2023 by Tassos Gianakakos. Jun 15, 2026 15th June 2026 | Hong Kong United States heart drug biotech company Kardigan Nasdaq IPO is raising $373 million at $1.4 billion valuation, with expected IPO listing on 18th June 2026. Kardigan was co-founded in 2023 by Tassos Gianakakos. Kardigan - Kardigan is a patient-driven heart health company that is modernizing cardiovascular drug development to deliver medicines that move patients beyond symptom management to functional cures. By matching critical disease drivers with treatment responders identified in clinical trials, Kardigan is developing a portfolio of medicines that modify the underlying cardiovascular disease pathophysiology to get patients closer to the cures they deserve. Kardigan has significant East and West Coast operations and focus. "United States heart drug biotech company Kardigan Nasdaq IPO to raise $373 million at $1.4 billion valuation with expected IPO listing on 18th June 2026, co-founded in 2023 by Tassos Gianakakos"